title: Prostate cancer risk after anti-androgen treatment for priapism.
abstract: BACKGROUND
  Patients with recurrent ischemic priapism have historically been treated with anti-androgen therapy due to the limited available evidence for more targeted therapies to treat the underlying pathophysiologic mechanisms of this condition. We report a case in which anti-androgen therapy caused significant adverse side effects and likely masked this patient's elevated prostate-specific antigen (PSA) levels, which adversely impacted the timely diagnosis and treatment of his prostate cancer.
  
  
  METHODS
  A 69-year-old man treated with anti-androgens for priapism initially developed unwanted anti-androgenic side effects such as gynecomastia, erectile dysfunction, and decreased libido. After decreasing his anti-androgen dosage and starting a specified regimen of phosphodiesterase type 5 inhibitor therapy, his serum PSA levels were found to be elevated. He was subsequently diagnosed with adenocarcinoma of the prostate and underwent a radical prostatectomy with the pathologic finding of high-grade, locally progressive disease.
  
  
  CONCLUSIONS
  Anti-androgen therapy carries significant complication risks, including the potential to alter the diagnosis and treatment of prostate cancer. Clinicians administering this therapy for priapism management should be aware of these possible risks.
authors.affiliation: Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, The Johns Hopkins Medical Institutions, 600 N. Wolfe St/Marburg 407, Baltimore, MD, 21287-2411, USA.
authors.forename: Tabitha
authors.initials: T
authors.lastname: Goetz
authors.forename: Arthur L
authors.initials: AL
authors.lastname: Burnett
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis*; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects*; D000813:Anilides / Q000009:adverse effects*; D057210:Delayed Diagnosis; D006801:Humans; D008297:Male; D009570:Nitriles / Q000009:adverse effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011317:Priapism / Q000188:drug therapy*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D011687:Purines / Q000627:therapeutic use; D055502:Secondary Prevention; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D014105:Tosyl Compounds / Q000009:adverse effects*
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014105:Tosyl Compounds; C053541:bicalutamide; D000068677:Sildenafil Citrate; D017430:Prostate-Specific Antigen